TY - JOUR
T1 - Triple-negative breast cancer is not a contraindication for breast conservation
AU - Adkins, Farrell C.
AU - Gonzalez-Angulo, Ana Maria
AU - Lei, Xiudong
AU - Hernandez-Aya, Leonel F.
AU - Mittendorf, Elizabeth A.
AU - Litton, Jennifer K.
AU - Wagner, Jamie
AU - Hunt, Kelly K.
AU - Woodward, Wendy A.
AU - Meric-Bernstam, Funda
PY - 2011/10
Y1 - 2011/10
N2 - Background: Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high risk of locoregional recurrence (LRR). The purpose of this study was to determine the impact of operation type on LRR in TNBC patients. Methods: A total of 1325 patients with TNBC who underwent breast-conserving therapy (BCT) or mastectomy from 1980 to the present were identified. Clinical and pathological factors were compared by the chi-square test. LRR-free survival (LRRFS), distant metastasis-free survival, and overall survival were estimated by the Kaplan-Meier method. Multivariate analysis was performed by the Cox proportional hazard models. Results: BCT was performed in 651 patients (49%) and mastectomy in 674 (51%). The mastectomy group had larger tumors, a higher incidence of lymphovascular invasion, and higher pathologic N stage (all P <0.001). At 62-month median follow-up, LRR was seen in 170 (26%) in the BCT group and 203 (30%) in the mastectomy group. Five-year LRRFS rates were higher in the BCT group (76% vs. 71%, P = 0.032), as was distant metastasis-free survival (68% vs. 54%, P <0.0001) and overall survival (74% vs. 63%, P <0.0001). On multivariate analysis, T stage (hazard ratio [HR] 1.37, P = 0.006), high nuclear grade (HR 1.92, P = 0.002), lymphovascular invasion (HR 1.93, P <0.0001), close/positive margins (HR 1.89, P <0.0001), and use of non-anthracycline or taxane-based adjuvant chemotherapy (HR 2.01, P <0.0001) increased the LRR risk, while age [50 years was protective (HR 0.73, P = 0.007). Operation type (mastectomy vs. BCT, HR 1.07, P = 0.55) was not statistically significant. Conclusions: BCT is not associated with increased LRR rates compared to mastectomy. TNBC should not be considered a contraindication for breast conservation.
AB - Background: Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high risk of locoregional recurrence (LRR). The purpose of this study was to determine the impact of operation type on LRR in TNBC patients. Methods: A total of 1325 patients with TNBC who underwent breast-conserving therapy (BCT) or mastectomy from 1980 to the present were identified. Clinical and pathological factors were compared by the chi-square test. LRR-free survival (LRRFS), distant metastasis-free survival, and overall survival were estimated by the Kaplan-Meier method. Multivariate analysis was performed by the Cox proportional hazard models. Results: BCT was performed in 651 patients (49%) and mastectomy in 674 (51%). The mastectomy group had larger tumors, a higher incidence of lymphovascular invasion, and higher pathologic N stage (all P <0.001). At 62-month median follow-up, LRR was seen in 170 (26%) in the BCT group and 203 (30%) in the mastectomy group. Five-year LRRFS rates were higher in the BCT group (76% vs. 71%, P = 0.032), as was distant metastasis-free survival (68% vs. 54%, P <0.0001) and overall survival (74% vs. 63%, P <0.0001). On multivariate analysis, T stage (hazard ratio [HR] 1.37, P = 0.006), high nuclear grade (HR 1.92, P = 0.002), lymphovascular invasion (HR 1.93, P <0.0001), close/positive margins (HR 1.89, P <0.0001), and use of non-anthracycline or taxane-based adjuvant chemotherapy (HR 2.01, P <0.0001) increased the LRR risk, while age [50 years was protective (HR 0.73, P = 0.007). Operation type (mastectomy vs. BCT, HR 1.07, P = 0.55) was not statistically significant. Conclusions: BCT is not associated with increased LRR rates compared to mastectomy. TNBC should not be considered a contraindication for breast conservation.
UR - http://www.scopus.com/inward/record.url?scp=83055196951&partnerID=8YFLogxK
U2 - 10.1245/s10434-011-1920-z
DO - 10.1245/s10434-011-1920-z
M3 - Article
C2 - 21947595
AN - SCOPUS:83055196951
SN - 1068-9265
VL - 18
SP - 3164
EP - 3173
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 11
ER -